Advertisement

Latest Articles in finance

AstraZeneca Starts To Make Modest Profit From COVID Vaccine

The Anglo-Swedish company's third-quarter results showed the vaccine contributed one cent to core earnings per share of $1.08, a rise of 14 per cent. Total product sales jumped 49 per cent to $9.74 billion, as its vaccine sales topped $1 billion.

Read More

Morepen Labs Q2 Results: Net Profit Up 38%

The company has planned to treble the API capacity from present 310 KL to 1000 KL in the coming 24 months at the same site in Baddi (HP) within the same plant and at the additional land adjoining the site for which all approvals are in place, he added.

Read More

AstraZeneca Pharma India Q2 Results: Net Profit Declines 55%

Its revenue from operations during July-September 2021 stood at Rs 197.70 crore. It was Rs 209.47 crore for the same period a year ago, it added.

Read More

Wockhardt’s Q2 FY22 Revenue Grew By 21% Over Q2 FY21

The Company recorded substantial growth in Revenue (up by 21 per cent over previous corresponding quarter) and in EBITDA at Rs 109 crore compared to a nominal profit of Rs 27 crore in the corresponding quarter of the previous year.

Read More

Gland Pharma Looking At Complex Injectables, Biosimilar Space To Fuel Future Growth

The Hyderabad-based drug firm noted that it has made good progress in the R&D field for planned submission batches for complex injectables to be filed in the current financial year.

Read More

Tarsons Forays Into Rs 24,000 Cr Global Market For PCR, Cell Culture Products

The company got approval from the capital market regulator SEBI on October 29 for the initial public offering. It will raise Rs 150 crore fresh capital, while 1.32 crore shares will be on offer for sale from promoters and a private equity investor. There is no company in India into PCR and cell/tiss

Read More

Changing How India Pays For Healthcare

We need to change the way we pay for our healthcare and bridge the gap between what our health insurance pays for and our family’s actual healthcare expenses.

Read More

J&J Settles Most Risperdal Lawsuits, With $800 Mn In Expenses

J&J said in a filing with the U.S. Securities and Exchange Commission on Friday that it reached a settlement in principle in September to resolve 'substantially all' of the roughly 9,000 cases that the New Brunswick, New Jersey-based drugmaker faced over Risperdal.

Read More

Delta Variant, Shortages Severely Restrict US Economic Growth In Q3

The weaker-than-expected growth reported by the Commerce Department on Thursday also reflected decreasing pandemic relief money from the government to businesses, state and local governments as well as households.

Read More

Zydus Wellness At Rs 21 Cr Profit In Q2

Revenue from operations for the second quarter of FY22 stood at Rs 380.13 crore as against Rs 340.32 crore in the year-ago period.

Read More